Rics; FC: Fold modify. Competing interests A patent was filed (DP, DT, RZ). Authors’ contributions DP, DT, and RZ concepted and made the study. DP, GH, ESch, and AW performed microarray and RT-qPCR experiments. EO performed the multiplexed immunoassays. DP made the microarray bioinformatics and DP, GH, and MK analyzed the data statistically. SA, JS, IB, IV, TVG, SM, NC, and PS recruited patients, collected patient samples and information, and revised the manuscript critically. DP, SA and RZ wrote the manuscript and all authors read and approved the final manuscript. Acknowledgements This function was supported by the Sixth Framework Programme (FP6) Project of the European Union (EU) referred to as “Ovarian Cancer: Diagnosis of a silent killer ?OVCAD”, no. 018698, the Austrian Science Fund (FWF) project, no. I 1216-B19, and also the Ludwig Boltzmann Cluster “Translational Oncology”. We thank Ingrid Schiebl for her excellent technical help. Author facts Department of Obstetrics and Gynecology, Molecular Oncology Group, Health-related University of Vienna, European Union, Vienna, Austria. 2Ludwig Boltzmann Cluster “Translational Oncology”, General Hospital Vienna, European Union, Waehringer Guertel 18-20, Room-No.: five.Q9.27, A-1090, Vienna, Austria. 3Section for Clinical Biometrics, Center for Healthcare Statistics, Informatics and Intelligent Systems, Medical University of Vienna, European Union, Vienna, Austria.Buytert-Butyl 4-bromopicolinate 4Department of Gynecology, Campus Virchow Klinikum, Charite Medical University, European Union, Berlin, Germany. five Department of Obstetrics and Gynecology, Division of Gynecological Oncology, University Hospitals Leuven, Katholieke Universiteit Leuven, European Union, Leuven, Belgium. 6Division of Gynaecological Oncology, Division of Obstetrics and Gynaecology, MUMC+, Grow ?College for Oncology and Developmental Biology, European Union, Maastricht, The Netherlands. 7Department of Gynecology and Gynecologic Oncology, University Healthcare Center Hamburg-Eppendorf, European Union, Hamburg, Germany. 8Department of Gynecology and Obstetrics, Innsbruck Health-related University, European Union, Innsbruck, Austria.Received: 25 July 2012 Accepted: 18 March 2013 Published: 3 AprilPils et al. BMC Cancer 2013, 13:178 http://biomedcentral/1471-2407/13/Page 13 ofReferences 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225?49. 2. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma with the ovary. FIGO 26th annual report around the outcomes of treatment in gynecological cancer.4-Bromo-5-ethoxyfuran-2(5H)-one Order Int J Gynaecol Obstet 2006, 95(Suppl 1):S161 192. 3. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma.PMID:23563799 J Clin Invest 1981, 68(5):1331?337. 4. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004, three(four):355?66. 5. Moore RG, Maclaughlan S: Present clinical use of biomarkers for epithelial ovarian cancer. Curr Opin Oncol 2010, 22(5):492?97. six. Mabuchi S, Kimura T: Therapy of ovarian cancer by monoclonal antibodies. Discov Med 2010, 9(46):197?03. 7. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, et al: Three biomarkers identified from serum proteomic evaluation for the detection of early stage ovarian cancer. Cancer Res 2004, 64(16):5882?890. eight. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S,.
